XORTX Pharma Corp. is pleased to announce the appointment of Mr. Bruce Rowlands to the XORTX Board of Directors, effective November 28, 2014. This appointment increases the XORTX Board of Directors to four members including Mr. Robert Reider, Mr. Bruce Rowlands, Dr. Alan Moore and Dr. Allen Davidoff – President and CEO.

Mr. Rowlands has 25 years sales, operations, capital markets and senior management experience with emerging market companies. Mr. Rowlands is the current Chairman and Chief Executive Officer of Eurocontrol Technics Group, a TSXV listed company that is focused on the acquisition and development of certification and authentication technologies. Prior to forming Eurocontrol, Mr. Rowlands worked in the biotechnology and investment banking industries as Senior Vice President with Lorus Therapeutics, a leading Canadian biotechnology company, and Vice President and Director of Dominick and Dominick Securities Canada, a Canadian investment banking firm.

Dr. Allen Davidoff, President and CEO of XORTX Pharma Corp. stated, “Bruce Rowlands is a key addition to the XORTX Board of Directors and brings an important blend of solid biotechnology experience combined with a wealth of capital markets experience. With the upcoming RTO with Bradmer Pharmaceuticals Inc. announced last week and pending financing, we look forward to his contribution to the Company’s future progress and success.”

About Mr. Robert Rieder: Mr. Rieder is currently the CEO of ESSA Pharma Inc., and Chairman of the Board of Cardiome Pharma Corp.

About Dr. Alan Moore: Currently, Founding Board Member, XORTX Pharma Corp. and his most recent CEO position was with ChiRegen. Before that he acted as CEO of BetaStem Therapeutics and Stem Cell Therapeutics. He has also held the positions of Executive Vice President, R&D at Cardiome Pharma Inc. and he was the creator of the Cardiac research and development therapeutic area at Procter & Gamble resulting in a NDA filing for the lead antiarrhythmic compound, Azimilide.

About Dr. Allen Davidoff: Dr. Allen W. Davidoff, Ph.D. is the President and CEO of XORTX Pharma Corp. since 2012. Prior to joining XORTX, he held the position of Vice President, Product Development and Chief Scientific Officer with Stem Cell Therapeutics Corp. from 2005 through 2012 and Senior Scientist and Head of Pharmacology at Cardiome Pharma in 2003 and 2004.

Bradmer Pharmaceuticals Inc. announced last week that it is planning to complete a going-public transaction for XORTX.

About XORTX Pharma Corp. is a pharmaceutical company dedicated to the discovery, development and commercialization of therapies for rare diseases –orphan indications – and diseases caused by disrupted uric acid metabolism that will improve patient health throughout the world. The primary focus of XORTX Pharma Corp. is based on developing treatments to
better manage uric acid metabolism for treatment of autosomal dominant polycystic kidney disease when accompanied by hyperuricemia. Secondary programs include the development of uric acid lowering agents to treat diabetes, treat diabetic nephropathy and treat hereditary hypouricemia.

XORTX Pharma Corp. is a privately held company. For more information, please visit our web site at www.xortx.com.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Risks, uncertainties and factors that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks, uncertainties and factors related to the fact that: we, together with our collaborative partners, may not be able to successfully develop all or any of our current or future products and may not be able to obtain regulatory approval in targeted indications for our current or future products in all markets; we may not achieve or maintain profitability; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital as and when required; we depend on our collaborative partners to perform their obligations under licensing or other collaborative agreements; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; any of our products that obtain regulatory approval will be subject to extensive post-market regulation that may affect sales, marketing and profitability; any of our products that are successfully developed may not achieve market acceptance; we rely on third parties for the continued supply and manufacture of our products and have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters, including with respect to our ability to protect our intellectual property; we face increased competition from pharmaceutical and biotechnology companies; and other. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.